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Type 1 Diabetes Mellitus Immunotherapy: 

















































Type	 1	 Diabetes	 Mellitus	 (T1DM)	 is	 a	 chronic	 autoimmune	 disease	 where	 insulin-
producing	 pancrea6c	 ß	 cells	 are	 eﬃciently	 destroyed	 by	 autoreac6ve	 T	 cells,	 causing	


















Regulatory	 T	 cells	 belong	 to	 a	 suppressive	 T	 cell	 lineage	 that	 regulate	 T	 cell	 responses,	

















































Since	 the	 Treg	 popula<on	 is	 disbalanced	 in	 T1DM	pa<ents,	 immunotherapies	 increasing	 this	 popula<on	 seem	 the	 ﬁbest	 possibility	 for	 the	 disease	 reversion.	 Among	 all	







Ex	 vivo	 therapies	 are	 based	 on	 an	 isolated	 T	 Reg	 popula6on	 by	 FACS,	 later	 expanded	 by	
diﬀerent	 an6gen-speciﬁc	methods	 and	 then	 reinfused	 again	 into	 the	 pa6ent.	 The	 aim	 is	 to	
obtain	suﬃcient	T	reg	numbers	for	the	disease	regression.	
MODELS	 MODELS	
The	an6gens	used	for	this	therapies	correspond	to	the	ﬁrst	an6gens	against	which	
autoan6bodies	are	created:	
Isola6on	can	be	achieved	eﬃciently	by	FACS	as	described	in	Figure	1.	Several	
methods	have	been	described	to	speciﬁcally	expand	T	reg	cells:	
ü Easy	to	administer	
ü 	Well-studied	
ü 	Global	therapy	
X 	Side	eﬀects	
X 	Aier-diagnosis	 ü 	Less	side	eﬀects	
ü Personalized	
ü 	More	T	reg	numbers	
X 	Therapeu6c	dose?	
X 	Aier-	
			diagnosis	
Author:	Raquel	Crespo	Galván 	 	Microbiology	Bachelor	
Teﬀ:	Eﬀector	T	cells	
Treg:	Regulatory	T	cells	
GadAlum	 Diapep277	
NBI-604	
• GAD65	(Pancrea6c	enzyme	
an6gen)	+	Alum	
• Immunodominant	pep6de	
p277	from	HSP60	(Heat	Shock	
Protein)	
• Altered	pep6de	ligand	of	B9-23	(insulin	
immunodominant	an6gen)	
*	Clinical	trials:	Phase	II	
•  Shii	the	cytokine	enviroment	à	an6-inﬂamatory	
•  Immunomodulatory	cytokines	(IL-5,	IL-10,	TGFß)	
•  Blockade	T	cell	func6on,	prolifera6on	and	diﬀerencia6on	
•  T	reg	induc6on	
•  Less	insulin	need	
•  Disease	regression	
natural	T	Reg	 induced	T	Reg	
•  APC:	ar6ﬁcial/dendri6c	cells	
•  an6C-D3	/	an6-CD28	+	IL-2	
•  HLA	class	II	tetramers	(pep6de-MHC	
complexes)	
•  GILZ-DC	
*	Clinical	trials:	Phase	II	
•  Supress	eﬀector	cell	responses	(infused	cells)	
•  Augment	T	reg	numbers	
•  Augment	C-pep6de	levels	
•  Less	insulin	need	
•  Disease	regression	
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